Fredun Pharmaceuticals Ltd
BSE:539730
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd. engages in the manufacture and sale of pharmaceuticals, neutraceuticals, herbal and dietary supplements. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2016-03-17. The firm is primarily engaged in the business of pharmaceuticals and healthcare. The company operates through pharmaceutical formulation segment. The company offers a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. The company is also engaged in the manufacturing of dietary /herbal supplements, nutraceuticals, and other healthcare products along with animal healthcare products. The firm primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.
Fredun Pharmaceuticals Ltd. engages in the manufacture and sale of pharmaceuticals, neutraceuticals, herbal and dietary supplements. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2016-03-17. The firm is primarily engaged in the business of pharmaceuticals and healthcare. The company operates through pharmaceutical formulation segment. The company offers a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. The company is also engaged in the manufacturing of dietary /herbal supplements, nutraceuticals, and other healthcare products along with animal healthcare products. The firm primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.
Strong Growth: Fredun Pharmaceuticals reported robust Q2 FY '26 results, with total income up 35% YoY and net profit up 128%.
Profitability: EBITDA margin improved to 15.37%, and operating cash flows turned positive, reflecting ongoing efficiency gains.
New Verticals: Significant momentum in nutraceuticals, pet care, and mobility, with pet wellness driving strong contributions.
Pet Care Expansion: Acquisitions of One Pet Stop and Wagr.ai enhance Fredun’s connected pet wellness ecosystem and digital offerings.
Innovative Products: Launch of Snacky Jain, India’s first pure Jain functional pet food, met with exceptional market demand.
Capacity Expansion: Manufacturing expansion at Palghar to boost capacity, efficiency, and meet rising demand in domestic and export markets.
Guidance Maintained: Management reiterated commitment to FY '29 PAT target of INR 90 crore, emphasizing a conservative approach.
